Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th – February 19th, 2021.

Read this article:
Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 p.m. ET.

Continue reading here:
Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.

See more here:
GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,896,552 common shares of Aeterna, at a price to the public of $1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

Originally posted here:
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 20,509,746 common shares of Aeterna, at a price to the public of $1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

Read this article:
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:

See the original post here:
Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.

Read more:
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Here is the original post:
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

Basel, February 17, 2021 — Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease.

See the original post here:
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities…

PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment will begin in France and Belgium for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.

See the rest here:
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities...